BioMed Pulse Journal | Open Access • Peer-Reviewed • Multidisciplinary

Abstract

Mini Review • Volume1-Issue1

Immune Dysregulation and Hematologic Interactions in HIV and Infectious Diseases: Implications for Vaccination and Allergic Responses

Lorna Galleguillos

Received: 2026-01-05 | Accepted: 2026-01-15 | Published: 2026-01-21
Pages: 1-2
OCLC Number:

Abstract

HIV infection and other chronic infectious diseases profoundly alter immune regulation, hematologic homeostasis, and inflammatory pathways. These alterations influence susceptibility to opportunistic infections, vaccine responsiveness, hematologic abnormalities, and allergic manifestations. Understanding the interconnected mechanisms linking immunodeficiency, immune activation, and blood disorders is essential for improving preventive and therapeutic strategies. This mini review synthesizes current knowledge on immune dysregulation in HIV and infectious diseases, with particular focus on hematologic complications, vaccine responses, and allergic phenomena. Emerging insights highlight the need for integrated immunologic and hematologic approaches in patient management.

Full Text (HTML) Full Text (PDF) DOI: 10.37871/bmpj1117
Copyright

© 2026 Galleguillos L. Distributed under Creative Commons CC-BY 4.0

How to Cite this Article

Galleguillos L. Immune Dysregulation and Hematologic Interactions in HIV and Infectious Diseases: Implications for Vaccination and Allergic Responses. BioMed Pulse J. 2026 Jan 21; 1(1): 0.

Subject Area(s)

Hematology HIV/AIDS Immunology

References

  1. AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2023.
  2. World Health Organization. HIV/AIDS fact sheet. Geneva: WHO; 2023.
  3. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–1533.
  4. Pantaleo G, Graziosi C, Fauci AS. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993;328(5):327–335.
  5. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med. 2009;60:471–484.
  6. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013;21(1):6–13.
  7. Estes JD, et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat Med. 2017;23(11):1271–1276.
  8. Fenwick C, et al. T-cell exhaustion in HIV infection. Immunol Rev. 2019;292(1):149–163.
  9. Moir S, Fauci AS. B-cell responses to HIV infection. Immunol Rev. 2017;275(1):33–48.
  10. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in HIV-infected persons. J Acquir Immune Defic Syndr. 1998;19(1):29–34.
  11. Sloand EM. Hematologic complications of HIV infection. AIDS Rev. 2005;7(4):187–196.
  12. Bain BJ. The haematological features of HIV infection. Br J Haematol. 1997;99(1):1–8.
  13. Scaradavou A. HIV-related thrombocytopenia. Blood Rev. 2002;16(1):73–76.
  14. Crum-Cianflone NF, et al. Vaccination in HIV-infected adults. Infect Dis Clin North Am. 2014;28(2):273–303.
  15. Cooper C, et al. Immunization in HIV-infected adults: a review. Hum Vaccin Immunother. 2015;11(3):1–10.
  16. Tebas P. Vaccination for HIV-infected individuals. Clin Infect Dis. 2019;68(5):1–8.
  17. Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
  18. Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
  19. HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington (DC): Department of Health and Human Services; 2023.
  20. Pirmohamed M, Park BK. HIV and drug hypersensitivity reactions. Nat Rev Immunol. 2001;1(2):109–120.
  21. Phillips EJ, Mallal SA. HLA-B*57:01 screening and abacavir hypersensitivity. N Engl J Med. 2008;358(6):568–579.
  22. French MA. Immune reconstitution inflammatory syndrome. Clin Infect Dis. 2009;48(1):101–107.
  23. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for IRIS. AIDS. 2005;19(4):399–406.
  24. Pachter LM, et al. Infection and asthma/allergy interactions. J Allergy Clin Immunol. 2010;125(2):1–12.
  25. Holt PG, Sly PD. Viral infections and atopy. Nat Rev Immunol. 2012;12(4):295–305.
  26. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023.
  27. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in aging and disease. Nat Med. 2019;25(12):1822–1832.
  28. Funderburg NT, Lederman MM. Coagulation and inflammation in HIV. Curr Opin HIV AIDS. 2014;9(4):1–7.
  29. Lundgren JD, et al. Initiation of antiretroviral therapy in early HIV infection. N Engl J Med. 2015;373(9):795–807.
  30. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
  31. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV. MMWR Recomm Rep. 2009;58(RR-4):1–207.
  32. Brenchley JM, Douek DC. The mucosal barrier in HIV infection. Nat Med. 2008;14(8):826–834.

Comments